Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Given Consensus Rating of “Moderate Buy” by Analysts

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has earned a consensus rating of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation, six have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $81.6667.

A number of analysts have weighed in on the stock. Morgan Stanley boosted their target price on shares of Arrowhead Pharmaceuticals from $48.00 to $81.00 and gave the stock an “equal weight” rating in a research note on Wednesday, January 7th. Chardan Capital boosted their price objective on shares of Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the stock a “buy” rating in a research note on Wednesday, January 7th. HC Wainwright reissued a “buy” rating and issued a $100.00 price objective on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, March 25th. The Goldman Sachs Group boosted their price objective on shares of Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a research note on Wednesday, January 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $110.00 price objective (up from $100.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, January 13th.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $65.14 on Monday. The firm’s fifty day moving average price is $61.91 and its two-hundred day moving average price is $56.03. The stock has a market cap of $9.12 billion, a PE ratio of 42.58 and a beta of 1.26. Arrowhead Pharmaceuticals has a fifty-two week low of $10.75 and a fifty-two week high of $76.76. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its earnings results on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share for the quarter, missing analysts’ consensus estimates of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to the consensus estimate of $225.66 million. Arrowhead Pharmaceuticals had a return on equity of 35.64% and a net margin of 18.54%.The business’s quarterly revenue was up 10461.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($1.39) EPS. On average, equities analysts expect that Arrowhead Pharmaceuticals will post -2.42 EPS for the current fiscal year.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In related news, insider James C. Hamilton sold 10,000 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $64.19, for a total value of $641,900.00. Following the sale, the insider owned 236,958 shares of the company’s stock, valued at $15,210,334.02. The trade was a 4.05% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 3.60% of the stock is currently owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Institutional investors have recently modified their holdings of the business. Tsfg LLC bought a new stake in shares of Arrowhead Pharmaceuticals in the fourth quarter worth $25,000. iSAM Funds UK Ltd bought a new stake in shares of Arrowhead Pharmaceuticals in the third quarter worth $29,000. First Horizon Corp bought a new stake in Arrowhead Pharmaceuticals during the fourth quarter valued at $32,000. Salomon & Ludwin LLC bought a new stake in Arrowhead Pharmaceuticals during the third quarter valued at $34,000. Finally, WPG Advisers LLC boosted its position in Arrowhead Pharmaceuticals by 384.8% during the fourth quarter. WPG Advisers LLC now owns 543 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 431 shares during the last quarter. Institutional investors own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.